Andreas Johne

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Machine Learning

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

JCO precision oncology

Clinical and translational science

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Federico Amato, Rainer Strotmann, Roberto Castello, Rolf Bruns, Vishal Ghori, Andreas Johne, Karin Berghoff, Karthik Venkatakrishnan, Nadia Terranova
Explainable machine learning prediction of edema adverse events in patients treated with tepotinib. Clinical and translational science 17 (9) (2024)
Shukui Qin, Hongming Pan, Jean Frédéric Blanc, Véronique Grando, Ho Yeong Lim, Xin Ying Chang, Aurora O'Brate, Christopher Stroh, Manja Friese-Hamim, Joachim Albers, Andreas Johne, Sandrine Faivre
Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence. JCO precision oncology 8 (2024)
Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat
The preclinical pharmacology of tepotinib - a highly selective MET inhibitor with activity in tumors harboring MET alterations. Molecular cancer therapeutics (2023)
Chong-Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, Jian-Ying Zhou, Dong Wan Kim, Ross Andrew Soo, Ying Cheng, Shun Lu, Sang Won Shin, James Chih-Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi-Long Wu
Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)